Versant Capital Management’s Entrada Therapeutics TRDA Stock Holding History

Versant Capital Management’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.1K	Buy	4,221 +175	+4%	+$1.68K	﹤0.01%	1696
2026 Q1	$51.1K	Hold	4,046	–	–	0.01%	1231
2025 Q4	$41.6K	Buy	4,046 +27	+0.7%	+$228	0.01%	1187
2025 Q3	$23.3K	Buy	4,019 +2,555	+175%	+$14.9K	﹤0.01%	1502
2025 Q2	$9.84K	Buy	+1,464	New	+$11.8K	﹤0.01%	1898

Other funds holding TRDA

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Versant Capital Management's TRDA Position: Q2 2026 in Review

Versant Capital Management increased its Entrada Therapeutics (TRDA) stake by 4.3% in Q2 2026, buying an estimated $1.68K and bringing the position to 4,221 shares worth $31.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1696.

Versant Capital Management first reported a position in TRDA in Q2 2025 and has held it in 5 quarters since. The position peaked at $51.1K in Q1 2026. 15 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

Versant Capital Management held 4,221 shares of Entrada Therapeutics worth $31.1K as of Q2 2026.
Versant Capital Management bought 175 Entrada Therapeutics shares in Q2 2026, an estimated $1.68K.
Entrada Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1696 holding.
Versant Capital Management first reported a position in Entrada Therapeutics in Q2 2025 and has held it in 5 quarters since.
Versant Capital Management's Entrada Therapeutics position peaked at $51.1K in Q1 2026.
15 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.